Title:
慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤
Document Type and Number:
Japanese Patent JP4854198
Kind Code:
B2
Abstract:
The invention relates to a combination which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, navembichin, phenestrine, prednimustine, trofosfamide or uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula or a pharmaceutically acceptable salt thereof, the invention pertains to the use of said combination for the treatment chronic lymphocytic leukemia.
Inventors:
Lawrence Carl PANASCI
Raquel Silvia ALOYZ
Raquel Silvia ALOYZ
Application Number:
JP2004551110A
Publication Date:
January 18, 2012
Filing Date:
November 10, 2003
Export Citation:
Assignee:
Jewish General Hospital
Lawrence Carl PANASCI
Raquel Silvia ALOYZ
Lawrence Carl PANASCI
Raquel Silvia ALOYZ
International Classes:
A61K31/506; A61K31/196; A61K31/505; A61P35/02; A61P43/00
Other References:
BLOOD,2000年,Vol.96, No.11, Part 1,Page.82a
Oncologie,2002年,Vol.4,page.373-375
T. de Witte, J. -P. Marieb, S. Suciuc, O. Anak,Highlights and strategies of the EORTC Leukemia Group,European Journal of Cancer,2002年,Vol.38, Suppl.4,Page.94-99
Oncologie,2002年,Vol.4,page.373-375
T. de Witte, J. -P. Marieb, S. Suciuc, O. Anak,Highlights and strategies of the EORTC Leukemia Group,European Journal of Cancer,2002年,Vol.38, Suppl.4,Page.94-99
Attorney, Agent or Firm:
Aoyama Aoi
Mitsutaka Iwasaki
Mitsuo Tanaka
Mitsutaka Iwasaki
Mitsuo Tanaka